Black Seed for Hypertension

Verdict: Modest blood-pressure benefit, not a treatment

Black seed (Nigella sativa) consistently produces a small reduction in blood pressure in trials, but the effect is modest and unproven as a stand-alone therapy. We rate it Preliminary Evidence: a plausible adjunct, not a substitute for proven hypertension treatment.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Three meta-analyses point the same direction. A 2016 review of 11 RCTs (n=860; PMID 27512971) found systolic BP fell about 3.3 mmHg and diastolic about 2.8 mmHg; a 2023 update (PMID 37341696) reported roughly 3.1 and 2.7 mmHg; and a 2025 GRADE-assessed dose-response analysis of 82 trials (n=5,026; PMID 40714301) again found significant improvement. The signal is real but small.

Several caveats keep this at a preliminary grade rather than higher. The benefit rests on a surrogate measure (blood pressure), not hard cardiovascular outcomes; trials are mostly small and short with largely undisclosed funding; statistical heterogeneity is substantial (I-squared near 60%); and preparations are inconsistent (the 2016 analysis favored powder, the 2023 update favored oil). A dedicated trial in elderly hypertensives (PMID 29348380) found only a non-significant downward trend, so the effect does not clearly generalize.

No authority endorses it for blood pressure. The US FDA recognizes black seed only as a GRAS spice and flavoring (21 CFR 182.10), with no approved health claim; Cleveland Clinic is cautious, while Mayo Clinic, Harvard Health and major societies do not address it. Because black seed can add to or interact with antihypertensive drugs, anyone on BP medication should use it only under medical supervision.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.57
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.70
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.573
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure
PMID: 27512971 2016 統合分析 n = 860
Finding: Across 11 RCTs (860 normotensive/hypertensive individuals, mean 8.3 weeks), N. sativa significantly reduced SBP (WMD -3.26 mmHg, 95% CI -5.10 to -1.42) and DBP (WMD -2.80 mmHg, 95% CI -4.28 to -1.32); short-term treatment with N. sativa powder can significantly reduce BP.
Effect size: WMD SBP -3.26 mmHg; DBP -2.80 mmHg
View on PubMed
Antihypertensive effects of Nigella sativa supplementation: An updated systematic review and meta-analysis of randomized controlled trials
PMID: 37341696 2023 統合分析
Finding: Updated meta-analysis found N. sativa supplementation significantly reduced SBP (WMD -3.06 mmHg, 95% CI -3.89 to -2.22, p<0.001) and DBP (WMD -2.69 mmHg, 95% CI -3.72 to -1.66, p<0.001); concludes N. sativa could be used as an effective approach to BP management.
Government Effect size: WMD SBP -3.06 mmHg; DBP -2.69 mmHg
View on PubMed
Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials
PMID: 40714301 2025 統合分析 n = 5,026
Finding: Comprehensive GRADE-assessed dose-response meta-analysis of 82 RCTs (5026 participants) found N. sativa supplementation significantly improved both SBP and DBP, alongside lipids, glycemic markers and inflammatory markers; positioned as a promising adjunct therapy for CVD risk factors.
Effect size: Significant SBP and DBP improvement; magnitude not detailed in abstract
View on PubMed
Effect of Nigella sativa Seed Extract for Hypertension in Elderly: a Double-blind, Randomized Controlled Trial
PMID: 29348380 2017 隨機對照試驗 n = 76
Finding: In elderly hypertensive patients, SBP fell 160.4 to 145.8 mmHg (N. sativa) vs 160.9 to 147.5 mmHg (placebo, p=0.36) and DBP 78.3 to 74.4 vs 79.0 to 78.2 mmHg (p=0.35); only a slight non-significant downward trend, N. sativa not proven effective in this population.
Effect size: SBP between-group difference NS (p=0.36); DBP NS (p=0.35)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
black cumin (black caraway), Nigella sativa L. — listed as a spice and other natural seasoning and flavoring (21 CFR 182.10), GRAS source↗
L4b EU EFSA
Neutral
L4d TW TFDA / 衛福部
Neutral
黑種草能食用的部位是黑種草籽油,只要適量食用,不會有特別的風險。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-black-seed-001 繁體中文版 →